On the 22nd, Idience, the new drug development subsidiary of Ildong Pharmaceutical, announced that they have presented the research findings related to 'Venadaparib' at the 2024 ASCO Gastrointestinal Cancers Symposium held from the 18th to the 20th.

Venadaparib is a novel targeted anticancer candidate product with a mechanism focused on selective inhibition of ‘Poly ADP-ribose polymerase (PARP).’ Idience is currently engaged in clinical development efforts for various cancer types, including gastric cancer, breast cancer, ovarian cancer, and cancers with resistance to PARP inhibitors.

Idience participated in a poster session at the symposium where they shared interim results fro